Evidence map›Paper›PMID 35235193›Full record

ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2022

Addition time plays a major role in the inhibitory effect of chitosan on the production of Pseudomonas aeruginosa virulence factors.

P Kašparová, S Boková, M Rollová, M Paldrychová, E Vaňková, K Lokočová, J Michailidu, O Maťátková, J Masák

Open access · greenAbstract read
In one paragraph

Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Non-thermal plasma causesFrontiers in cellular and infection microbiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

P KašparováDepartment of Biotechnology, University of Chemistry and Technology in Prague, Technická 5, Prague 6 - Dejvice, 166 28, Czech Republic. kasparop@vscht.cz.ORCID http://orcid.org/0000-0003-2182-0430
S BokováDepartment of Biotechnology, University of Chemistry and Technology in Prague, Technická 5, Prague 6 - Dejvice, 166 28, Czech Republic.ORCID http://orcid.org/0000-0001-5252-6643
M RollováDepartment of Biotechnology, University of Chemistry and Technology in Prague, Technická 5, Prague 6 - Dejvice, 166 28, Czech Republic.
M PaldrychováDepartment of Biotechnology, University of Chemistry and Technology in Prague, Technická 5, Prague 6 - Dejvice, 166 28, Czech Republic.
E VaňkováDepartment of Biotechnology, University of Chemistry and Technology in Prague, Technická 5, Prague 6 - Dejvice, 166 28, Czech Republic.ORCID http://orcid.org/0000-0001-8863-0696
K LokočováDepartment of Biotechnology, University of Chemistry and Technology in Prague, Technická 5, Prague 6 - Dejvice, 166 28, Czech Republic.ORCID http://orcid.org/0000-0003-0107-2287
J MichailiduDepartment of Biotechnology, University of Chemistry and Technology in Prague, Technická 5, Prague 6 - Dejvice, 166 28, Czech Republic.ORCID http://orcid.org/0000-0003-2679-2408
O MaťátkováDepartment of Biotechnology, University of Chemistry and Technology in Prague, Technická 5, Prague 6 - Dejvice, 166 28, Czech Republic.ORCID http://orcid.org/0000-0002-3646-9738
J MasákDepartment of Biotechnology, University of Chemistry and Technology in Prague, Technická 5, Prague 6 - Dejvice, 166 28, Czech Republic.ORCID http://orcid.org/0000-0001-6484-0824
University of Chemistry and Technology, Prague · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pseudomonas aeruginosa is a gram-negative bacterium capable of forming persistent biofilms that are extremely difficult to eradicate. The species is most infamously known due to complications in cystic fibrosis patients. The high mortality of cystic fibrosis is caused by P. aeruginosa biofilms occurring in pathologically overly mucous lungs, which are the major cause facilitating the organ failure. Due to Pseudomonas biofilm-associated infections, remarkably high doses of antibiotics must be administered, eventually contributing to the development of antibiotic resistance. Nowadays, multidrug resistant P. aeruginosa is one of the most terrible threats in medicine, and the search for novel antimicrobial drugs is of the utmost importance. We have studied the effect of low molecular weight chitosan (LMWCH) on various stages of P. aeruginosa ATCC 10145 biofilm formation and eradication, as well as on production of other virulence factors. LMWCH is a well-known naturally occurring agent with a vast antimicrobial spectrum, which has already found application in various fields of medicine and industry. LMWCH at a concentration of 40 mg/L was able to completely prevent biofilm formation. At a concentration of 60 mg/L, this agent was capable to eradicate already formed biofilm in most studied times of addition (2-12 h of cultivation). LMWCH (50 mg/L) was also able to suppress pyocyanin production when added 2 and 4 h after cultivation. The treatment resulted in reduced formation of cell clusters. LMWCH was proved to be an effective antibiofilm agent worth further clinical research with the potential to become a novel drug for the treatment of P. aeruginosa infections.

Indexed as

ChitosanCystic FibrosisPseudomonas InfectionsAnti-Bacterial AgentsBiofilmsHumansPseudomonas aeruginosaVirulence FactorsAnti-Bacterial AgentsChitosanVirulence FactorsBiofilmEradicationFormationLow molecular weight chitosanPseudomonas aeruginosaVirulence factors

Identifiers

PMID35235193
PMCPMC9151934
OpenAlexW4214828668

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.